Echinacoside

Echinacoside at a Glance

Echinacoside is a caffeoyl phenylethanoid glycoside (PhG) — a caffeic-acid ester joined through a rhamnose–glucose sugar core to a hydroxytyrosol (dihydroxyphenylethanol) unit. Structurally it is a close relative of verbascoside (acteoside), differing mainly by an extra glucose, and the two almost always occur together in the same plants ^{17Reference 17Fu Z et al. · 2018Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics propertyView study →}.

Its name comes from Echinacea — it was first isolated from Echinacea angustifolia roots in 1950, and it is a species marker of the narrow-leaf and pale coneflowers (but not the popular E. purpurea, which uses cichoric acid and caftaric acid instead). Despite the name, the overwhelming majority of echinacoside research comes from a different plant entirely: Cistanche (Chinese rou cong rong, “desert-hyacinth”), a parasitic desert herb whose fleshy stems are one of the richest known sources and where echinacoside is treated as the principal active compound ^{17,18Reference 17Fu Z et al. · 2018Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics propertyView study →Reference 18Baidya R et al. · 2025Systematic reviewA systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycosideView study →}.

The marquee claim is neuroprotection — a large preclinical literature in Parkinson’s- and Alzheimer’s-disease animal models — flanked by anti-fatigue, bone-protective, hepatoprotective and antioxidant signals. All of it carries one caveat that reframes the rest of the page: echinacoside is poorly absorbed and extensively hydrolysed by gut bacteria, so nearly every finding is in an isolated cell or animal model, and there is no isolated-molecule human trial ^{14,16Reference 14Shen JY et al. · 2015Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oilView study →Reference 16Li Y et al. · 2016Screening and identification of three typical phenylethanoid glycosides metabolites from Cistanches Herba by human intestinal bacteria using UPLC/Q-TOF-MSView study →}.

The Cistanche Connection

The single most important thing to understand about echinacoside is the gap between its name and its literature. It is named for Echinacea, and in the Western herbal world it is filed as “an echinacea compound.” But Echinacea is not why echinacoside is studied.

In traditional Chinese medicine, the fleshy stems of Cistanche deserticola and Cistanche tubulosa (rou cong rong) are a prized tonic, and echinacoside — together with verbascoside/acteoside — is the dominant phenylethanoid glycoside behind their reputation as a “brain” and longevity herb ^{17,18Reference 17Fu Z et al. · 2018Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics propertyView study →Reference 18Baidya R et al. · 2025Systematic reviewA systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycosideView study →}. The Chinese Pharmacopoeia quality-controls Cistanche on echinacoside content, and virtually all of the neuroprotection, anti-fatigue and bone research uses Cistanche-derived echinacoside ^{17Reference 17Fu Z et al. · 2018Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics propertyView study →}.

The practical consequence: when you read that “echinacoside protects dopaminergic neurons,” the compound was almost always sourced from Cistanche, not coneflower. In Echinacea itself, echinacoside sits within the ~2% caffeic-acid-derivative fraction as one antioxidant marker among several, and coneflower’s own (modest) evidence is for whole-herb immune effects, not for isolated echinacoside ^{19Reference 19Sharifi-Rad M et al. · 2018Echinacea plants as antioxidant and antibacterial agents: From traditional medicine to biotechnological applicationsView study →}. This page keeps that source split explicit throughout.

What It's Used For

Echinacoside’s pharmacology is deep on the preclinical side and empty on the human-trial side. The evidence sorts by disease model, and every row shares the same bioavailability discount.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume, and tempered for isolate-vs-plant match and bioavailability. A beta, not a validated metric. Every score here is capped by the absence of human data.

01Neuroprotection — Parkinson’s / DopaminergicPromising52%Many concordant rodent MPTP/6-OHDA studies + resolved mechanisms; Cistanche isolate; no human trial ^{1,2,4,5Reference 1Geng X et al. · 2007AnimalNeuroprotective effects of echinacoside in the mouse MPTP model of Parkinson’s diseaseView study →Reference 2Yang X et al. · 2022Echinacoside Protects Dopaminergic Neurons Through Regulating IL-6/JAK2/STAT3 Pathway in Parkinson’s Disease ModelView study →Reference 4Gao MR et al. · 2020Echinacoside protects dopaminergic neurons by inhibiting NLRP3/Caspase-1/IL-1β signaling pathway in MPTP-induced Parkinson’s disease modelView study →Reference 5Chen C et al. · 2019Echinacoside protects against MPTP/MPP+-induced neurotoxicity via regulating autophagy pathway mediated by Sirt1View study →}

02Neuroprotection — Alzheimer’s / CognitionShaky40%Amyloid reduction + memory rescue in mouse AD models; isolate/extract; preclinical ^{7,9Reference 7Dai Y et al. · 2020AnimalEchinacoside Suppresses Amyloidogenesis and Modulates F-actin Remodeling by Targeting the ER Stress Sensor PERK in a Mouse Model of Alzheimer’s DiseaseView study →Reference 9Zhou R et al. · 2025AnimalEchinacoside Improves Memory Function and Bone Mineral Density in the Aged SAMP8 Mouse ModelView study →}

03Antioxidant (Phenolic)Shaky32%Catechol radical-scavenging; as an extract constituent of Echinacea & Cistanche ^{19Reference 19Sharifi-Rad M et al. · 2018Echinacea plants as antioxidant and antibacterial agents: From traditional medicine to biotechnological applicationsView study →}

04HepatoprotectionShaky32%Rodent alcohol- & metabolic-steatosis models (PPARα, Nrf2 ferroptosis); isolate; preclinical ^{11,12Reference 11Tao Z et al. · 2021Echinacoside ameliorates alcohol-induced oxidative stress and hepatic steatosis by affecting SREBP1c/FASN pathway via PPARαView study →Reference 12Yan Y et al. · 2024Echinacoside Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease by Inhibiting Ferroptosis via Nrf2/HMOX1 PathwayView study →}

05Bone / OsteoporosisShaky30%Osteoclast inhibition in vitro + bone-density rescue in aged/AD-comorbid rodents ^{10,9,8Reference 10Jiang T et al. · 2022Echinacoside Inhibits Osteoclast Function by Down-Regulating PI3K/Akt/C-Fos to Alleviate Osteolysis Caused by Periprosthetic Joint InfectionView study →Reference 9Zhou R et al. · 2025AnimalEchinacoside Improves Memory Function and Bone Mineral Density in the Aged SAMP8 Mouse ModelView study →Reference 8Chen Y et al. · 2020AnimalEstablishment of the concurrent experimental model of osteoporosis combined with Alzheimer’s disease in rat and the dual-effects of echinacoside and acteoside from Cistanche tubulosaView study →}

06Anti-Fatigue / AdaptogenicShaky24%Small rodent altitude-fatigue study; the traditional Cistanche tonic rationale ^{13Reference 13Ziliang G et al. · 2023AnimalEfficacy of verbascoside, echinacoside, crenatoside on altitude-induced fatigue in rats and possible mechanismView study →}

How Echinacoside Works

Echinacoside’s effects converge on a small set of themes rather than a single receptor. As a polyphenol with several catechol groups, its baseline action is antioxidant — direct radical scavenging and metal chelation, plus upregulation of endogenous defences such as the Nrf2/HO-1 (HMOX1) axis ^{12Reference 12Yan Y et al. · 2024Echinacoside Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease by Inhibiting Ferroptosis via Nrf2/HMOX1 PathwayView study →}. On top of that sits a consistent anti-neuroinflammatory action: suppression of the NLRP3 inflammasome, NF-κB, and microglial activation, which is why its Parkinson’s and Alzheimer’s results look mechanistically similar ^{3,4,7Reference 3Yang XP et al. · 2024Echinacoside exerts neuroprotection via suppressing microglial α-synuclein/TLR2/NF-κB/NLRP3 axis in parkinsonian modelsView study →Reference 4Gao MR et al. · 2020Echinacoside protects dopaminergic neurons by inhibiting NLRP3/Caspase-1/IL-1β signaling pathway in MPTP-induced Parkinson’s disease modelView study →Reference 7Dai Y et al. · 2020AnimalEchinacoside Suppresses Amyloidogenesis and Modulates F-actin Remodeling by Targeting the ER Stress Sensor PERK in a Mouse Model of Alzheimer’s DiseaseView study →}. A third theme is pro-survival / pro-autophagy signalling — Sirt1-mediated autophagy and JAK2/STAT3 modulation with raised BDNF, which shifts stressed neurons away from apoptosis ^{2,5Reference 2Yang X et al. · 2022Echinacoside Protects Dopaminergic Neurons Through Regulating IL-6/JAK2/STAT3 Pathway in Parkinson’s Disease ModelView study →Reference 5Chen C et al. · 2019Echinacoside protects against MPTP/MPP+-induced neurotoxicity via regulating autophagy pathway mediated by Sirt1View study →}.

The load-bearing point: these are well-resolved mechanisms in cells and rodents, but each was demonstrated at concentrations delivered directly to the tissue — a bar that oral echinacoside’s poor absorption may never clear (see Pharmacokinetics).

Pharmacokinetics

Pharmacokinetics is echinacoside’s Achilles’ heel and the reason its rich preclinical record has not become a drug. It is a large, highly polar tri-glycoside, so it crosses membranes poorly and its absolute oral bioavailability is very low — intact echinacoside barely reaches the systemic circulation ^{14Reference 14Shen JY et al. · 2015Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oilView study →}. Worse, it is extensively hydrolysed by intestinal bacteria before absorption: gut flora cleave the sugars and the caffeoyl ester, so much of what “echinacoside” does in vivo may actually be the work of smaller downstream metabolites (hydroxytyrosol, caffeic-acid and phenylethanoid fragments) rather than the parent glycoside ^{16Reference 16Li Y et al. · 2016Screening and identification of three typical phenylethanoid glycosides metabolites from Cistanches Herba by human intestinal bacteria using UPLC/Q-TOF-MSView study →}.

This is exactly the profile of its sibling verbascoside, whose absolute oral bioavailability is around 0.12% in rats — and it is why formulation work dominates the PK literature. Co-administration with verapamil or clove oil raised echinacoside exposure by roughly 1.4- and 2.4-fold respectively (implicating efflux transport and mucosal permeability as barriers) ^{14Reference 14Shen JY et al. · 2015Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oilView study →}, and a phospholipid complex improved its intestinal absorption several-fold ^{15Reference 15Li F et al. · 2015Phospholipid complex as an approach for bioavailability enhancement of echinacosideView study →}. That so much effort targets absorption is itself the clearest statement of the problem: without help, oral echinacoside is a poorly-absorbed molecule, and every potent in-vitro concentration should be read against that fact.

Clinical Trials

There are no completed clinical trials of isolated echinacoside for any indication. The human evidence that exists belongs to whole Cistanche or Echinacea preparations, within which echinacoside is one standardised marker rather than the tested entity — and even those trials do not attribute outcomes to the isolate. The Parkinson’s, Alzheimer’s, bone, liver and fatigue results are entirely preclinical ^{6,18Reference 6Li J et al. · 2022Therapeutic Potential and Molecular Mechanisms of Echinacoside in Neurodegenerative DiseasesView study →Reference 18Baidya R et al. · 2025Systematic reviewA systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycosideView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

Echinacoside sits at an unusual midpoint. Unlike many plant phenolics, most of its mechanistic studies do use the isolated molecule — purified echinacoside (typically from Cistanche) dosed into cells and rodents — which is a genuine strength for mechanism ^{1,2,4Reference 1Geng X et al. · 2007AnimalNeuroprotective effects of echinacoside in the mouse MPTP model of Parkinson’s diseaseView study →Reference 2Yang X et al. · 2022Echinacoside Protects Dopaminergic Neurons Through Regulating IL-6/JAK2/STAT3 Pathway in Parkinson’s Disease ModelView study →Reference 4Gao MR et al. · 2020Echinacoside protects dopaminergic neurons by inhibiting NLRP3/Caspase-1/IL-1β signaling pathway in MPTP-induced Parkinson’s disease modelView study →}. The weakness is at both ends of that pipeline: the source plant is usually Cistanche, not the Echinacea its name implies, so the data do not straightforwardly transfer to coneflower products ^{17Reference 17Fu Z et al. · 2018Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics propertyView study →}; and the isolate’s poor bioavailability means even a clean in-vitro result may not survive oral dosing intact ^{14,16Reference 14Shen JY et al. · 2015Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oilView study →Reference 16Li Y et al. · 2016Screening and identification of three typical phenylethanoid glycosides metabolites from Cistanches Herba by human intestinal bacteria using UPLC/Q-TOF-MSView study →}. Where whole-plant work exists it is for Cistanche or Echinacea extracts standardised to echinacoside, not for the compound alone. So the honest reading is: strong isolated-molecule mechanism, no isolated-molecule human outcome, and a source-plant mismatch to keep in view.

Its Role in Plants

In its plant sources echinacoside is a phenylethanoid glycoside of the caffeic-acid/caffeoyl family, built biosynthetically from the phenylpropanoid pathway (phenylalanine → cinnamic → caffeic acid) esterified onto a tyrosol-derived aglycone and decorated with rhamnose and glucose. Functionally, PhGs like echinacoside and verbascoside act as antioxidant and defence phenolics — UV and oxidative-stress protectants and deterrents against herbivores and pathogens.

Its distribution is ecologically telling. In Cistanche, a root-parasitic desert plant with no photosynthesis, PhGs including echinacoside accumulate to extraordinary levels in the fleshy stems (a large fraction of dry matter is phenylethanoid glycoside), consistent with a heavy investment in chemical protection ^{17Reference 17Fu Z et al. · 2018Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics propertyView study →}. In Echinacea it is a root marker whose presence and level are species-specific — abundant in E. angustifolia and E. pallida roots but essentially absent from E. purpurea, which builds cichoric and caftaric acids instead ^{18,19Reference 18Baidya R et al. · 2025Systematic reviewA systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycosideView study →Reference 19Sharifi-Rad M et al. · 2018Echinacea plants as antioxidant and antibacterial agents: From traditional medicine to biotechnological applicationsView study →}. These are plant-biology roles and should not be read as human pharmacology.

Prevalence in Nature

Echinacoside occurs across the order Lamiales and in the family Asteraceae, but two genera dominate its story.

Cistanche (Orobanchaceae) is the richest source and the origin of most research material: the fleshy stems of C. tubulosa and C. deserticola hold echinacoside at percent-of-dry-weight levels, and the Chinese Pharmacopoeia sets a minimum echinacoside-plus-acteoside content of ~1.2% for C. tubulosa and ~0.3% for C. deserticola ^{17Reference 17Fu Z et al. · 2018Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics propertyView study →}. C. tubulosa can reach several percent ^{20Reference 20Liu B et al. · 2013Adsorption properties and preparative separation of phenylethanoid glycosides from Cistanche deserticola by use of macroporous resinsView study →}.

Echinacea (Asteraceae) gave the molecule its name: it is a root marker of E. angustifolia and E. pallida at roughly 0.2–1% dry weight, but is absent from the widely sold E. purpurea ^{18,19Reference 18Baidya R et al. · 2025Systematic reviewA systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycosideView study →Reference 19Sharifi-Rad M et al. · 2018Echinacea plants as antioxidant and antibacterial agents: From traditional medicine to biotechnological applicationsView study →}. It also appears as a minor phenylethanoid glycoside in other Lamiales such as Forsythia.

Major Natural Sources

Source	Part	Typical echinacoside	Notes
Cistanche tubulosa	fleshy stem	~1.2–4% dry wt	richest source; pharmacopoeial marker; research material 17,20Reference 17Fu Z et al. · 2018Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics propertyView study →Reference 20Liu B et al. · 2013Adsorption properties and preparative separation of phenylethanoid glycosides from Cistanche deserticola by use of macroporous resinsView study →
Cistanche deserticola	fleshy stem	~0.3–1.8% dry wt	pharmacopoeial marker (rou cong rong) 17Reference 17Fu Z et al. · 2018Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics propertyView study →
Echinacea angustifolia	root	~0.3–1% dry wt	species marker; the naming source 18Reference 18Baidya R et al. · 2025Systematic reviewA systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycosideView study →
Echinacea pallida	root	~0.1–0.3% dry wt	species marker 18Reference 18Baidya R et al. · 2025Systematic reviewA systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycosideView study →
Echinacea purpurea	—	absent	uses cichoric/caftaric acid instead 19Reference 19Sharifi-Rad M et al. · 2018Echinacea plants as antioxidant and antibacterial agents: From traditional medicine to biotechnological applicationsView study →

Discovery & Synthesis

Echinacoside was first isolated in 1950 by Arthur Stoll, Jean Renz and André Brack at Sandoz, from the roots of Echinacea angustifolia, and reported in Helvetica Chimica Acta — the isolation that gave the molecule its name ^{18Reference 18Baidya R et al. · 2025Systematic reviewA systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycosideView study →}. Its full structure as a caffeoyl phenylethanoid glycoside (a disaccharide-linked hydroxytyrosol caffeate carrying an extra glucose relative to verbascoside) was resolved over subsequent decades. A practical total synthesis is not well documented — like most complex glycosylated natural products, it is far more economically obtained by extraction than by synthesis.

Manufacture today is almost entirely by extraction from Cistanche stems, not from Echinacea: Cistanche is the far richer source, and purification typically uses macroporous-resin adsorption, which can enrich crude Cistanche extract from ~1.8% echinacoside to purified fractions of 15%+ ^{20Reference 20Liu B et al. · 2013Adsorption properties and preparative separation of phenylethanoid glycosides from Cistanche deserticola by use of macroporous resinsView study →}. Commercial echinacoside is therefore a Cistanche product, reinforcing the name-versus-source gap that defines this compound.

Patents: not yet researched.

Toxicity & Safety

Echinacoside carries a low toxicity flag. It is a constituent of two plants with long records of dietary and medicinal use — Cistanche stems are a traditional tonic food-herb, and Echinacea is among the most widely used Western botanicals — and the isolated compound has not shown notable toxicity in the many rodent studies that dosed it, often at 20–50 mg/kg/day, without reported adverse findings ^{6,18Reference 6Li J et al. · 2022Therapeutic Potential and Molecular Mechanisms of Echinacoside in Neurodegenerative DiseasesView study →Reference 18Baidya R et al. · 2025Systematic reviewA systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycosideView study →}. Its poor systemic absorption further limits the plausibility of isolate toxicity from oral exposure.

The honest limits are about missing data, not observed harm: there is no dedicated human safety dataset, no formal drug-interaction study, and no reproductive-toxicity package for the isolated molecule. Interaction potential is plausible in theory given the transporter/permeability interactions used to boost its absorption (e.g. verapamil, a P-glycoprotein substrate/inhibitor) ^{14Reference 14Shen JY et al. · 2015Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oilView study →}, but this has not been characterised clinically.

Safety at a Glance

✅ Low / no toxicity

• Low apparent toxicity. A constituent of long-used Cistanche and Echinacea; well tolerated in rodent studies, and poorly absorbed orally.
• No human safety data on the isolate. No formal drug-interaction, repeat-dose or reproductive-toxicity studies exist for pure echinacoside.
• Source confusion. “Echinacoside” research is mostly from Cistanche; it is absent from E. purpurea, so Echinacea purpurea products contain little or none.
• Theoretical transporter interactions. Absorption is modulated by P-glycoprotein / permeability enhancers (verapamil, clove oil), a plausible but unstudied interaction route.

Dosage

There is no established human dose for isolated echinacoside. Preclinical studies typically use 20–50 mg/kg/day in rodents (orally or by injection), and Cistanche-extract human tonics are standardised to echinacoside content rather than dosed to an isolated-compound target. Because oral bioavailability is low and gut bacteria hydrolyse much of the intact glycoside, animal doses do not scale directly to a human dose ^{14,16Reference 14Shen JY et al. · 2015Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oilView study →Reference 16Li Y et al. · 2016Screening and identification of three typical phenylethanoid glycosides metabolites from Cistanches Herba by human intestinal bacteria using UPLC/Q-TOF-MSView study →}.

These are doses studied in research and are not a personal recommendation.

References

1. Geng X, et al. (2007). Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson’s disease. European Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/17359968/
2. Yang X, et al. (2022). Echinacoside Protects Dopaminergic Neurons Through Regulating IL-6/JAK2/STAT3 Pathway in Parkinson’s Disease Model. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/35281889/
3. Yang XP, et al. (2024). Echinacoside exerts neuroprotection via suppressing microglial α-synuclein/TLR2/NF-κB/NLRP3 axis in parkinsonian models. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/38000105/
4. Gao MR, et al. (2020). Echinacoside protects dopaminergic neurons by inhibiting NLRP3/Caspase-1/IL-1β signaling pathway in MPTP-induced Parkinson’s disease model. Brain Research Bulletin. https://pubmed.ncbi.nlm.nih.gov/32846198/
5. Chen C, et al. (2019). Echinacoside protects against MPTP/MPP+-induced neurotoxicity via regulating autophagy pathway mediated by Sirt1. Metabolic Brain Disease. https://pubmed.ncbi.nlm.nih.gov/30426321/
6. Li J, et al. (2022). Therapeutic Potential and Molecular Mechanisms of Echinacoside in Neurodegenerative Diseases. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/35185590/
7. Dai Y, et al. (2020). Echinacoside Suppresses Amyloidogenesis and Modulates F-actin Remodeling by Targeting the ER Stress Sensor PERK in a Mouse Model of Alzheimer’s Disease. Frontiers in Cell and Developmental Biology. https://pubmed.ncbi.nlm.nih.gov/33330477/
8. Chen Y, et al. (2020). Establishment of the concurrent experimental model of osteoporosis combined with Alzheimer’s disease in rat and the dual-effects of echinacoside and acteoside from Cistanche tubulosa. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/32278031/
9. Zhou R, et al. (2025). Echinacoside Improves Memory Function and Bone Mineral Density in the Aged SAMP8 Mouse Model. Molecular Neurobiology. https://pubmed.ncbi.nlm.nih.gov/41261317/
10. Jiang T, et al. (2022). Echinacoside Inhibits Osteoclast Function by Down-Regulating PI3K/Akt/C-Fos to Alleviate Osteolysis Caused by Periprosthetic Joint Infection. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/35814196/
11. Tao Z, et al. (2021). Echinacoside ameliorates alcohol-induced oxidative stress and hepatic steatosis by affecting SREBP1c/FASN pathway via PPARα. Food and Chemical Toxicology. https://pubmed.ncbi.nlm.nih.gov/33378712/
12. Yan Y, et al. (2024). Echinacoside Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease by Inhibiting Ferroptosis via Nrf2/HMOX1 Pathway. Biomedicines. https://pubmed.ncbi.nlm.nih.gov/39767635/
13. Ziliang G, et al. (2023). Efficacy of verbascoside, echinacoside, crenatoside on altitude-induced fatigue in rats and possible mechanism. Journal of Traditional Chinese Medicine. https://pubmed.ncbi.nlm.nih.gov/37679981/
14. Shen JY, et al. (2015). Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oil. Drug Design, Development and Therapy. https://pubmed.ncbi.nlm.nih.gov/26316707/
15. Li F, et al. (2015). Phospholipid complex as an approach for bioavailability enhancement of echinacoside. Drug Development and Industrial Pharmacy. https://pubmed.ncbi.nlm.nih.gov/25686726/
16. Li Y, et al. (2016). Screening and identification of three typical phenylethanoid glycosides metabolites from Cistanches Herba by human intestinal bacteria using UPLC/Q-TOF-MS. Journal of Pharmaceutical and Biomedical Analysis. https://pubmed.ncbi.nlm.nih.gov/26551535/
17. Fu Z, et al. (2018). Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics property. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/29054705/
18. Baidya R, et al. (2025). A systematic review of the traditional uses, chemistry, and curative aptitude of echinacoside — a phenylethanoid glycoside. Naunyn-Schmiedeberg’s Archives of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/39361172/
19. Sharifi-Rad M, et al. (2018). Echinacea plants as antioxidant and antibacterial agents: From traditional medicine to biotechnological applications. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/29749084/
20. Liu B, et al. (2013). Adsorption properties and preparative separation of phenylethanoid glycosides from Cistanche deserticola by use of macroporous resins. Journal of Chromatography B. https://pubmed.ncbi.nlm.nih.gov/24022055/

View all 20 references▾